因子XIa抑制剂asundexian的治疗应用探索
Asundexian是因子XIa小分子抑制剂,每日口服一次,20至50mg剂量可抑制约90%因子XIa活性。2期试验显示房颤等场景安全性可能优于标准治疗,但OCEANIC-AF 3期试验因疗效不及阿哌沙班提前终止。
要点
- Asundexian 20至50mg每日一次可抑制约90%因子XIa活性。
- 房颤中OCEANIC-AF因疗效不及阿哌沙班提前终止。
- 非心源性卒中或急性心梗联用抗血小板时出血与安慰剂无差异。
核心结论
- 因子XIa抑制剂可减弱病理性血栓而对止血干扰小,但asundexian在房颤卒中预防中疗效不及阿哌沙班。
研究设计与样本
- 综述总结asundexian的临床研究,涵盖2期试验及已启动的3期试验。
主要发现
- Asundexian 20至50mg剂量抑制约90%因子XIa活性。
- 房颤等场景2期试验显示安全性可能优于标准治疗。
- 非心源性卒中和急性心梗联用抗血小板时,出血事件发生率与安慰剂无差异。
关键数值与推荐
- Asundexian每日口服一次,20至50mg抑制约90%因子XIa活性。
- OCEANIC-AF因asundexian相比阿哌沙班在房颤卒中预防中无效而提前终止。
- OCEANIC-AFINA计划在不适合抗凝的高卒中风险房颤患者中比较asundexian与安慰剂。
临床怎么用
- 临床药师应关注asundexian在房颤卒中预防中疗效不及阿哌沙班,不宜替代现有抗凝标准。
- 在非心源性卒中或急性心梗联用抗血小板时,asundexian出血风险与安慰剂无差异,但需等待3期试验验证。
局限性
- OCEANIC-AF因无效提前终止,asundexian在房颤卒中预防中的疗效未达预期。
- 其他适应证的3期试验尚未完成,疗效和安全性证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Factor XIa inhibitors are a promising novel class of anticoagulants that attenuate pathological thrombosis with minimal interference with hemostasis. These effects contrast with those of conventional anticoagulants, which may exhibit adverse events of untoward bleeding precluding treatment in some patients. A variety of investigational pharmacological modalities have been developed and studied to target factor XIa. SUMMARY: Asundexian is a small molecule inhibitor of factor XIa that has been evaluated in several clinical studies. It has been studied as an oral, once-daily medication and found to inhibit approximately 90% of factor XIa activity at doses of 20 to 50 mg. Phase 2 trials have demonstrated the potential for improved safety compared to standard of care in certain treatment settings, such as in atrial fibrillation. For other indications, such as noncardioembolic stroke and acute myocardial infarction, asundexian has been used in addition to background antiplatelet therapy. In these instances, asundexian did not show a difference in the incidence of bleeding events compared to placebo. CONCLUSION: Phase 3 trials have recently been launched; however, the OCEANIC-AF trial was prematurely discontinued due to inefficacy of asundexian vs apixaban for stroke prevention in atrial fibrillation. Another phase 3 trial, OCEANIC-AFINA, is planned to compare asundexian to placebo in patients with atrial fibrillation at high risk for stroke who are deemed ineligible for anticoagulation.
引用
- Edwards J, Corey J, Coons JC, et al. Exploring the therapeutic utility of the factor XIa inhibitor asundexian. Am J Health Syst Pharm. 2024. PMID: 38995101. doi:10.1093/ajhp/zxae182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。